Blab Tech
Stereotaxis Completes Acquisition of Robocath, Expanding Its Endovascular Robotics Portfolio
On July 9 2026, Stereotaxis, the St. Louis‑based surgical‑robotics firm, announced that it has closed its purchase of French medtech company Robocath, a deal that could reshape the future of cardiovascular intervention.
The transaction, first disclosed in April, involved an upfront payment of $20 million and the possibility of an additional $25 million if regulatory and commercial milestones are met. Robocath was founded in 2009 by Dr. Philippe Bencteux, who remains CEO. Its flagship product, the R‑One+ robotic platform, assists cardiologists in performing percutaneous coronary interventions and has already earned CE certification in Europe and NMPA approval in China. The company is also developing a next‑generation version of the system.
Stereotaxis said the acquisition will accelerate the development of next‑generation robotic technologies for endovascular procedures. Chairman and CEO David Fischel stated that adding Robocath’s technology and team “accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities.” Bencteux echoed this enthusiasm, saying, “We’re very excited to join Stereotaxis. Combining the strengths, expertise, and technologies of two pioneers in endovascular robotics, we now have the opportunity to accelerate innovation, expand our global reach, and bring robotic solutions to many more physicians and patients around the world.”
Under the terms of the agreement, Robocath will become a wholly owned subsidiary of Stereotaxis. The company’s operations and development teams are expected to remain largely intact, and the R‑One+ platform will continue to be marketed under the Robocath brand. Stereotaxis plans to weave Robocath’s advanced technologies into its own next‑generation robotic surgical tools, targeting both interventional cardiology and electrophysiology markets.
The deal is subject to customary regulatory approvals and closing conditions. Stereotaxis had indicated in a prior announcement that the transaction was expected to close in mid‑2026, and the July 9 press release confirms that the deal has now been finalized.
Industry analysts note that the combined entity will be better positioned to compete in a growing market for cardiovascular intervention robots. According to market research, the global cardiovascular intervention robot market was valued at approximately $250 million in 2024 and is projected to reach $520 million by 2032, driven by increasing adoption of minimally invasive procedures and advances in robotic‑assisted systems.
Integrating Robocath’s R‑One+ platform with Stereotaxis’s existing robotic solutions could broaden the range of procedures that can be performed with robotic assistance, potentially improving procedural precision and patient outcomes. Both companies have emphasized the importance of safety and regulatory compliance; Robocath’s CE and NMPA certifications demonstrate that its systems meet stringent European and Chinese regulatory standards.
Fischel highlighted that the acquisition “provides attractive commercial synergies in an expanded addressable market.” The combined company will now have a broader product portfolio that spans the full spectrum of endovascular interventions, from coronary angioplasty to electrophysiology procedures.
The deal also positions Stereotaxis to leverage Robocath’s established presence in Europe and China, where the R‑One+ has already been deployed in several high‑volume cath labs. With the new partnership, Stereotaxis can accelerate the rollout of its next‑generation robotic systems in these regions.
As the acquisition closes, both firms have stated that they will continue to focus on innovation and regulatory compliance. Stereotaxis has indicated that it will maintain Robocath’s existing development teams and continue to support the R‑One+ platform while integrating the technology into its broader robotic ecosystem.
The completion of the deal marks a significant milestone for both firms. Stereotaxis now controls a larger portfolio of endovascular robotics technologies, while Robocath gains access to Stereotaxis’s resources and global reach. The combined entity is expected to play a larger role in the evolving landscape of minimally invasive cardiovascular care.
The transaction underscores the ongoing consolidation in the medtech robotics sector, as companies seek to broaden their product lines and expand into new markets. With the acquisition finalized, Stereotaxis and Robocath are poised to accelerate the development and deployment of robotic solutions that could improve the safety and efficacy of interventional procedures worldwide.
The transaction, first disclosed in April, involved an upfront payment of $20 million and the possibility of an additional $25 million if regulatory and commercial milestones are met. Robocath was founded in 2009 by Dr. Philippe Bencteux, who remains CEO. Its flagship product, the R‑One+ robotic platform, assists cardiologists in performing percutaneous coronary interventions and has already earned CE certification in Europe and NMPA approval in China. The company is also developing a next‑generation version of the system.
Stereotaxis said the acquisition will accelerate the development of next‑generation robotic technologies for endovascular procedures. Chairman and CEO David Fischel stated that adding Robocath’s technology and team “accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities.” Bencteux echoed this enthusiasm, saying, “We’re very excited to join Stereotaxis. Combining the strengths, expertise, and technologies of two pioneers in endovascular robotics, we now have the opportunity to accelerate innovation, expand our global reach, and bring robotic solutions to many more physicians and patients around the world.”
Under the terms of the agreement, Robocath will become a wholly owned subsidiary of Stereotaxis. The company’s operations and development teams are expected to remain largely intact, and the R‑One+ platform will continue to be marketed under the Robocath brand. Stereotaxis plans to weave Robocath’s advanced technologies into its own next‑generation robotic surgical tools, targeting both interventional cardiology and electrophysiology markets.
The deal is subject to customary regulatory approvals and closing conditions. Stereotaxis had indicated in a prior announcement that the transaction was expected to close in mid‑2026, and the July 9 press release confirms that the deal has now been finalized.
Industry analysts note that the combined entity will be better positioned to compete in a growing market for cardiovascular intervention robots. According to market research, the global cardiovascular intervention robot market was valued at approximately $250 million in 2024 and is projected to reach $520 million by 2032, driven by increasing adoption of minimally invasive procedures and advances in robotic‑assisted systems.
Integrating Robocath’s R‑One+ platform with Stereotaxis’s existing robotic solutions could broaden the range of procedures that can be performed with robotic assistance, potentially improving procedural precision and patient outcomes. Both companies have emphasized the importance of safety and regulatory compliance; Robocath’s CE and NMPA certifications demonstrate that its systems meet stringent European and Chinese regulatory standards.
Fischel highlighted that the acquisition “provides attractive commercial synergies in an expanded addressable market.” The combined company will now have a broader product portfolio that spans the full spectrum of endovascular interventions, from coronary angioplasty to electrophysiology procedures.
The deal also positions Stereotaxis to leverage Robocath’s established presence in Europe and China, where the R‑One+ has already been deployed in several high‑volume cath labs. With the new partnership, Stereotaxis can accelerate the rollout of its next‑generation robotic systems in these regions.
As the acquisition closes, both firms have stated that they will continue to focus on innovation and regulatory compliance. Stereotaxis has indicated that it will maintain Robocath’s existing development teams and continue to support the R‑One+ platform while integrating the technology into its broader robotic ecosystem.
The completion of the deal marks a significant milestone for both firms. Stereotaxis now controls a larger portfolio of endovascular robotics technologies, while Robocath gains access to Stereotaxis’s resources and global reach. The combined entity is expected to play a larger role in the evolving landscape of minimally invasive cardiovascular care.
The transaction underscores the ongoing consolidation in the medtech robotics sector, as companies seek to broaden their product lines and expand into new markets. With the acquisition finalized, Stereotaxis and Robocath are poised to accelerate the development and deployment of robotic solutions that could improve the safety and efficacy of interventional procedures worldwide.
